Tyra Biosciences, Inc. Share-based Payment Arrangement, Accelerated Cost
Tyra Biosciences, Inc. (TYRA) reported Share-based Payment Arrangement, Accelerated Cost of $2.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2026-03-02
- Tyra Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-09-30 was $2.00M.
- Tyra Biosciences, Inc. share-based payment arrangement, accelerated cost for fiscal 2024 was $2.00M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|
| 2024-12-31 | $2.00M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |